Silodosin information

Silodosin
Clinical data
Trade names	Urief, Rapaflo, Silodyx, others
Other names	KAD-3213, KMD-3213
AHFS/Drugs.com	Monograph
MedlinePlus	a609002
Routes of; administration	By mouth
ATC code	G04CA04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	32%
Protein binding	96.6%
Metabolism	Liver glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement
Elimination half-life	13±8 hours[citation needed]
Excretion	33.5% Kidney, 54.9% fecal
Identifiers
	IUPAC name 1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]indoline-7-carboxamide;
CAS Number	160970-54-7 ;
PubChem CID	5312125;
IUPHAR/BPS	493;
DrugBank	DB06207 ;
ChemSpider	4471557 ;
UNII	CUZ39LUY82;
KEGG	D01965;
ChEMBL	ChEMBL24778 ;
CompTox Dashboard (EPA)	DTXSID40167045 ;
ECHA InfoCard	100.248.664
Chemical and physical data
Formula	C25H32F3N3O4
Molar mass	495.543 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)COc3ccccc3OCCN[C@H](C)Cc1cc2c(c(c1)C(=O)N)N(CC2)CCCO;
	InChI InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1 ; Key:PNCPYILNMDWPEY-QGZVFWFLSA-N ;
	(what is this?) (verify)

Silodosin, sold under the brand name Urief among others, is a medication for the symptomatic treatment of benign prostatic hyperplasia.^[4]^[5] It acts as an alpha-1 adrenergic receptor antagonist.^[4]^[5]

The most common side effect is a reduction in the amount of semen released during ejaculation.^[5]

^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^ Cite error: The named reference Rapaflo CA was invoked but never defined (see the help page).
^ ^a ^b ^c "Rapaflo- silodosin capsule". DailyMed. 1 December 2020. Retrieved 5 March 2023.
^ ^a ^b ^c ^d "Silodyx EPAR". European Medicines Agency (EMA). 2010-01-10. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Cite error: The named reference Urorec EPAR was invoked but never defined (see the help page).

[1] "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.

[2] "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

[Rapaflo_CA-3] Cite error: The named reference Rapaflo CA was invoked but never defined (see the help page).

[Rapaflo_FDA_label-4] "Rapaflo- silodosin capsule". DailyMed. 1 December 2020. Retrieved 5 March 2023.

[Silodyx_EPAR-5] "Silodyx EPAR". European Medicines Agency (EMA). 2010-01-10. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Urorec_EPAR-6] Cite error: The named reference Urorec EPAR was invoked but never defined (see the help page).

Silodosin information

and 29 Related for: Silodosin information

Silodosin

Spontaneous orgasm

Aspermia

Rilmenidine

Benign prostatic hyperplasia

LSD

Kissei

Alpha blocker

Buspirone

Phenylephrine

Salbutamol

Promethazine

Adrenaline

Norepinephrine

Beta blocker

Quetiapine

Aripiprazole

Cyclobenzaprine

Tizanidine

Propranolol

Chlorpromazine

Hydroxyzine

Trazodone

Mirtazapine

Olanzapine

Mirabegron

Prochlorperazine

Clonidine

Finasteride